DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

Lexmark, a global imaging and IoT solutions leader, has been named a leader in the IDC MarketScape: Worldwide Cloud Managed Print and Document Services Hardcopy 2024 Vendor Assessment (Doc # ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

Stifel analyst Benjamin Burnett lowered the firm’s price target on Crispr Therapeutics (CRSP) to $49 from $53 and keeps a Hold rating on the ...

Edgewise Therapeutics (NASDAQ:EWTX) received an updated price target from JPMorgan, with analysts at the firm raising their ...

Viking Therapeutics (NASDAQ:VKTX – Free Report) had its target price lowered by Maxim Group from $120.00 to $70.00 in a research note issued to investors on Friday morning,Benzinga reports.

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains a buyer on share weakness following the Q4 report.

Our study investigated the brain circuits involved in psychosis-a condition characterized by delusions, hallucinations, ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

Canaccord Genuity maintained a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and significantly increased the price target to $45 from the previous $22. The adjustment reflects the firm's continued ...

Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic ... CEO at Hoth Therapeutics. "We are committed to driving innovative solutions ...

GOMEKLI™ is an oral, small molecule MEK inhibitor approved in the United States for the treatment of adult and pediatric ...